Literature DB >> 10588734

Soluble complexes of regulated upon activation, normal T cells expressed and secreted (RANTES) and glycosaminoglycans suppress HIV-1 infection but do not induce Ca(2+) signaling.

J M Burns1, G K Lewis, A L DeVico.   

Abstract

Chemokines comprise a family of low-molecular-weight proteins that elicit a variety of biological responses including chemotaxis, intracellular Ca(2+) mobilization, and activation of tyrosine kinase signaling cascades. A subset of chemokines, including regulated upon activation, normal T cell expressed and secreted (RANTES), macrophage inflammatory protein-1alpha (MIP-1alpha), and MIP-1beta, also suppress infection by HIV-1. All of these activities are contingent on interactions between chemokines and cognate seven-transmembrane spanning, G protein-coupled receptors. However, these activities are strongly inhibited by glycanase treatment of receptor-expressing cells, indicating an additional dependence on surface glycosaminoglycans (GAG). To further investigate this dependence, we examined whether soluble GAG could reconstitute the biological activities of RANTES on glycanase-treated cells. Complexes formed between RANTES and a number of soluble GAG failed to induce intracellular Ca(2+) mobilization on either glycanase-treated or untreated peripheral blood mononuclear cells and were unable to stimulate chemotaxis. In contrast, the same complexes demonstrated suppressive activity against macrophage tropic HIV-1. Complexes composed of (125)I-labeled RANTES demonstrated saturable binding to glycanase-treated peripheral blood mononuclear cells, and such binding could be reversed partially by an anti-CCR5 antibody. These results suggest that soluble chemokine-GAG complexes represent seven-transmembrane ligands that do not activate receptors yet suppress HIV infection. Such complexes may be considered as therapeutic formulations for the treatment of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588734      PMCID: PMC24465          DOI: 10.1073/pnas.96.25.14499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Polymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency viruses.

Authors:  S E Kuhmann; E J Platt; S L Kozak; D Kabat
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5.

Authors:  T Dragic; V Litwin; G P Allaway; S R Martin; Y Huang; K A Nagashima; C Cayanan; P J Maddon; R A Koup; J P Moore; W A Paxton
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

3.  Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5.

Authors:  D R Pakianathan; E G Kuta; D R Artis; N J Skelton; C A Hébert
Journal:  Biochemistry       Date:  1997-08-12       Impact factor: 3.162

4.  Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor.

Authors:  S Struyf; I De Meester; S Scharpé; J P Lenaerts; P Menten; J M Wang; P Proost; J Van Damme
Journal:  Eur J Immunol       Date:  1998-04       Impact factor: 5.532

5.  Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans.

Authors:  L Wagner; O O Yang; E A Garcia-Zepeda; Y Ge; S A Kalams; B D Walker; M S Pasternack; A D Luster
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

6.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.

Authors:  E Oberlin; A Amara; F Bachelerie; C Bessia; J L Virelizier; F Arenzana-Seisdedos; O Schwartz; J M Heard; I Clark-Lewis; D F Legler; M Loetscher; M Baggiolini; B Moser
Journal:  Nature       Date:  1996-08-29       Impact factor: 49.962

7.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Processing by CD26/dipeptidyl-peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1alpha.

Authors:  P Proost; S Struyf; D Schols; C Durinx; A Wuyts; J P Lenaerts; E De Clercq; I De Meester; J Van Damme
Journal:  FEBS Lett       Date:  1998-07-31       Impact factor: 4.124

9.  CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.

Authors:  M B Zaitseva; S Lee; R L Rabin; H L Tiffany; J M Farber; K W Peden; P M Murphy; H Golding
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  Heparan sulfate proteoglycan on leukemic cells is primarily involved in integrin triggering and its mediated adhesion to endothelial cells.

Authors:  Y Tanaka; K Kimata; A Wake; S Mine; I Morimoto; N Yamakawa; H Habuchi; S Ashikari; H Yamamoto; K Sakurai; K Yoshida; S Suzuki; S Eto
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

View more
  9 in total

1.  Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.

Authors:  J Mohamad Fakruddin; Richard A Lempicki; Robert J Gorelick; Jun Yang; Joseph W Adelsberger; Alfonso J Garcia-Pineres; Ligia A Pinto; H Clifford Lane; Tomozumi Imamichi
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

2.  Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140.

Authors:  A Trkola; T J Ketas; K A Nagashima; L Zhao; T Cilliers; L Morris; J P Moore; P J Maddon; W C Olson
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

Authors:  R Geiben-Lynn; M Kursar; N V Brown; E L Kerr; A D Luster; B D Walker
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Structural diversity of heparan sulfate binding domains in chemokines.

Authors:  Hugues Lortat-Jacob; Aurélien Grosdidier; Anne Imberty
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

Review 5.  Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy.

Authors:  Patricio E Ray
Journal:  Pediatr Nephrol       Date:  2009-03-14       Impact factor: 3.714

6.  GAG-DB, the New Interface of the Three-Dimensional Landscape of Glycosaminoglycans.

Authors:  Serge Pérez; François Bonnardel; Frédérique Lisacek; Anne Imberty; Sylvie Ricard Blum; Olga Makshakova
Journal:  Biomolecules       Date:  2020-12-11

7.  Structure of mouse IP-10, a chemokine.

Authors:  Talat Jabeen; Philip Leonard; Haryati Jamaluddin; K Ravi Acharya
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2008-05-14

8.  Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells.

Authors:  Christian Weingart; Peter J Nelson; Bernhard K Krämer; Matthias Mack
Journal:  BMC Immunol       Date:  2008-12-10       Impact factor: 3.615

Review 9.  Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation.

Authors:  Helena Crijns; Vincent Vanheule; Paul Proost
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.